ARTICLE | Clinical News
Revlimid lenalidomide regulatory update
June 20, 2011 7:00 AM UTC
The European Commission granted Orphan Drug designation for Celgene's Revlimid lenalidomide to treat diffuse large B cell lymphoma. The thalidomide analog is in Phase II/III testing for the indication...